The Goldman Sachs Group began coverage on shares of Olema Pharmaceuticals (NASDAQ:OLMA – Free Report) in a research report released on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $24.00 target price on the stock. Other equities analysts have also recently issued reports about the stock. Citigroup started coverage on shares […]